On 9 December 2024, MSD (known as Merck in the US and Canada) announced that its Phase 3 KEYLYNK-0001 trial for Keytruda® (pembrolizumab) plus chemotherapy, followed by maintenance with AstraZeneca’s Lynparza® (olaparib) (with or without bevacizumab) met its primary endpoint of progression-free survival in first line treatment of BRCA non-mutated advanced epithelial ovarian cancer. The secondary endpoint of overall survival was not met.
MSD intends to present the results at upcoming medical meetings and to discuss them with regulatory authorities.
These results follow positive results for MSD’s Phase 3 trial evaluating subcutaneous administration of pembrolizumab, together with Alteogen’s berahyaluronidase alfa, administered with chemotherapy, in adults with metastatic NSCLC.